Literature DB >> 8903327

Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

B K Reuter1, S Asfaha, A Buret, K A Sharkey, J L Wallace.   

Abstract

Cyclooxygenase type 1 is constitutively expressed and accounts for synthesis of prostaglandins in the normal gastrointestinal tract. Cyclooxygenase-2 is expressed at sites of inflammation. Selective inhibitors of cyclooxygenase-2 have been suggested to spare gastrointestinal prostaglandin synthesis, and therefore lack the ulcerogenic effects associated with standard nonsteroidal antiinflammatory drugs. However, the effects of cyclooxygenase-2 inhibitors on inflamed gastrointestinal mucosa have not been examined. We examined cyclooxygenase-2 mRNA and protein expression before and after induction of colitis in the rat, the contribution of cyclooxygenase-2 to colonic prostaglandin synthesis during colitis and the effects of selective inhibitors of cyclooxygenase-2 on colonic injury in this model. Cyclooxygenase-2 mRNA expression increased three to sixfold during the period 24 h to 1 wk after induction of colitis, with marked increases in cyclooxygenase-2 protein expression in the lamina propria and muscularis of the colon during colitis. Cyclooxygenase-1 expression (mRNA and protein) was not affected by the induction of colitis. The prostaglandins produced during colitis were largely derived from cyclooxygenase-2. Treatment with selective cyclooxygenase-2 inhibitors resulted in exacerbation of colitis, with perforation occurring when the compounds were administered for a week. These studies demonstrate that suppression of cyclooxygenase-2 can result in exacerbation of inflammation-associated colonic injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903327      PMCID: PMC507652          DOI: 10.1172/JCI119013

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Induction of cyclooxygenase type-2 (COX-2) in rat endometrium at the peak of serum estradiol during the estrus cycle.

Authors:  T Shoda; K Hatanaka; M Saito; M Majima; M Ogino; Y Harada; M Nishijima; M Katori; S Yamamoto
Journal:  Jpn J Pharmacol       Date:  1995-11

2.  Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.

Authors:  J L Wallace; W McKnight; P Del Soldato; A R Baydoun; G Cirino
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.

Authors:  C Gustafson-Svärd; I Lilja; O Hallböök; R Sjödahl
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

4.  Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1.

Authors:  K Glaser; M L Sung; K O'Neill; M Belfast; D Hartman; R Carlson; A Kreft; D Kubrak; C L Hsiao; B Weichman
Journal:  Eur J Pharmacol       Date:  1995-07-25       Impact factor: 4.432

5.  Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol).

Authors:  R J Flower; J R Vane
Journal:  Nature       Date:  1972-12-15       Impact factor: 49.962

6.  Inhibition of the n-formylmethionyl-leucyl-phenylalanine induced respiratory burst in human neutrophils by adrenergic agonists and prostaglandins of the E series.

Authors:  K Wong; K Freund
Journal:  Can J Physiol Pharmacol       Date:  1981-09       Impact factor: 2.273

7.  Regulation of macrophage tumor necrosis factor production by prostaglandin E2.

Authors:  S L Kunkel; R C Wiggins; S W Chensue; J Larrick
Journal:  Biochem Biophys Res Commun       Date:  1986-05-29       Impact factor: 3.575

8.  Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils.

Authors:  E A Ham; D D Soderman; M E Zanetti; H W Dougherty; E McCauley; F A Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.

Authors:  C C Chan; S Boyce; C Brideau; A W Ford-Hutchinson; R Gordon; D Guay; R G Hill; C S Li; J Mancini; M Penneton
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

10.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.

Authors:  R N DuBois; A Radhika; B S Reddy; A J Entingh
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  94 in total

1.  COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.

Authors:  B J Whittle
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 2.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects?

Authors:  I Bjarnason; K D Rainsford
Journal:  West J Med       Date:  2001-10

4.  Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study.

Authors:  H Goh; R Bourne
Journal:  Ann R Coll Surg Engl       Date:  2002-03       Impact factor: 1.891

Review 5.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

6.  Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice.

Authors:  Andrew P Neilson; Zora Djuric; Jianwei Ren; Yu H Hong; Ananda Sen; Corey Lager; Yan Jiang; Shony Reuven; William L Smith; Dean E Brenner
Journal:  J Nutr Biochem       Date:  2011-09-19       Impact factor: 6.048

7.  Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice.

Authors:  James A Lin; Junji Watanabe; Nora Rozengurt; Ajay Narasimha; Martin G Martin; Jenny Wang; Jonathan Braun; Robert Langenbach; Srinivasa T Reddy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-04-25       Impact factor: 3.072

8.  Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.

Authors:  Li Ma; Piero del Soldato; John L Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

9.  Protective role of hydrogen-rich water on aspirin-induced gastric mucosal damage in rats.

Authors:  Jing-Yao Zhang; Qi-Fei Wu; Yong Wan; Si-Dong Song; Jia Xu; Xin-Sen Xu; Hu-Lin Chang; Ming-Hui Tai; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

10.  Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells.

Authors:  Hon-Wai Koon; Dezheng Zhao; Yanai Zhan; Sang Hoon Rhee; Mary P Moyer; Charalabos Pothoulakis
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.